8-K: Seres Therapeutics Reports Q3 2025, Advances SER-155

Seres Therapeutics reported third quarter 2025 financial results, including net income from continuing operations, and is finalizing its SER-155 Phase 2 study protocol while actively seeking funding for its advancement.

Summary

• Reported net income from continuing operations of $8.2 million for Q3 2025, a significant improvement from a $51.0 million net loss in Q3 2024.
• The net income was primarily driven by a $27.2 million gain on the sale of the VOWST business, including a $25 million installment payment from Nestle.
• Loss from operations for Q3 2025 was $22.5 million, compared to $29.2 million in Q3 2024.
• Research and development (R&D) expenses decreased to $12.6 million in Q3 2025 from $16.5 million in Q3 2024, primarily due to lower personnel, platform investments, and completion of the SER-155 Phase 1b study.
• General and administrative (G&A) expenses decreased to $9.5 million in Q3 2025 from $12.7 million in Q3 2024, mainly due to lower personnel and IT-related costs.
• Seres is finalizing the SER-155 Phase 2 study protocol for preventing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), following constructive FDA feedback.
• The initiation of the SER-155 Phase 2 study and the anticipation of interim clinical results within 12 months of study start are dependent on securing additional capital and resources.
• The company implemented cost-reduction measures, including workforce reduction, and expects to fund operations through Q2 2026 based on current plans and cash position.
• As of September 30, 2025, Seres had $47.6 million in cash and cash equivalents.

Sentiment

Score: 6

Explanation: The strong clinical data for SER-155 and positive FDA feedback are significant positives, indicating high therapeutic potential. The net income from continuing operations is also a favorable financial metric, albeit driven by the VOWST sale. However, the ongoing operational loss and the explicit dependence on securing additional funding for the pivotal Phase 2 study introduce substantial financial uncertainty and risk, tempering overall sentiment.

Positives

• Achieved net income from continuing operations of $8.2 million in Q3 2025, a substantial improvement from a $51.0 million net loss in the prior year.
• Received a $25 million installment payment from Nestle related to the VOWST asset sale, contributing to a $27.2 million gain on sale.
• Successfully reduced R&D expenses by 23.6% to $12.6 million and G&A expenses by 25.3% to $9.5 million in Q3 2025 through cost-reduction measures, including workforce reduction.
• Received constructive FDA feedback and is finalizing the Phase 2 study protocol for SER-155, which has Breakthrough Therapy designation.
• SER-155 Phase 1b study demonstrated a 77% relative risk reduction in bacterial bloodstream infections (BSIs) and reduced systemic antibiotic exposure.
• Awarded a grant of up to $3.6 million from CARB-X to support the development of an oral liquid formulation of SER-155.
• Ongoing investigator-sponsored study for SER-155 in immune checkpoint related enterocolitis (irEC) is expected to provide initial efficacy results in early 2026, potentially expanding the therapeutic opportunity.

Negatives

• Despite net income from continuing operations, the company still reported a loss from operations of $22.5 million in Q3 2025.
• The advancement of the pivotal SER-155 Phase 2 study is explicitly dependent on securing additional capital and resources.
• Implemented cost-reduction measures, including a workforce reduction, indicating ongoing financial pressures.
• Current cash and cash equivalents of $47.6 million are projected to fund operations only through Q2 2026, necessitating further capital.

Risks

• Need for additional funding to support operations and advance clinical programs, particularly the SER-155 Phase 2 study.
• Ability to continue as a going concern is uncertain given historical losses and ongoing need for capital.
• Company has incurred significant losses, is not currently profitable, and may never become profitable.
• Cost reduction actions, including workforce reduction, may not achieve their intended benefits, such as extending the cash runway.
• Expected payments from the VOWST sale are subject to risks and uncertainties.
• May not be able to realize the anticipated benefits of the VOWST sale and may face new challenges as a smaller, less diversified company.
• Risk of receiving notice of failure to satisfy a continued listing rule from The Nasdaq Stock Market LLC.
• Reliance on third parties to conduct clinical trials and manufacture product candidates.
• Ability to achieve market acceptance necessary for commercial success of product candidates.
• Competition from other therapeutic approaches and companies.
• Ability to protect intellectual property.
• Challenges in managing recent CEO transition, retaining key personnel, and managing growth.
• Potential disruptions at the FDA or other government agencies affecting regulatory processes.

Future Outlook

The company is focused on advancing SER-155, with the Phase 2 study protocol being finalized following constructive FDA feedback. Initiation of this study and anticipated interim clinical results within 12 months are contingent on securing necessary funding. Efforts are ongoing to obtain capital and other resources to support SER-155 development and extend the cash runway beyond the projected Q2 2026. An investigator-sponsored study for SER-155 in immune checkpoint related enterocolitis is expected to complete enrollment by the end of 2025, with initial efficacy results anticipated in early 2026, potentially broadening SER-155's therapeutic scope. The company also continues to explore R&D partnerships for other investigational live biotherapeutics.

Management Comments

• "Following constructive feedback from the FDA, we are working to finalize our SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for hematological malignancies."
• "As we prepare for the next phase of SER-155 development, we continue our efforts aimed at securing the funding needed to conduct the Phase 2 study."
• "We expect to be ready to rapidly operationalize the study once financing is in place, and we expect to obtain interim efficacy and safety results within 12 months of the study start."
• "If these results are consistent with our prior successful Phase 1b study, and supportive of continued development, we believe this milestone should be a significant value-creating event for the Company and shareholders."
• "Based on our on-going engagement with the medical community and assessment of the commercial landscape, we remain highly enthusiastic about the broad potential for SER-155 in allo-HSCT and other medically vulnerable populations."
• "During the third quarter, we implemented cost-reduction measures, including decreasing our workforce. Considering these actions and our current operating plans, we expect to fund operations through the second quarter of 2026, providing flexibility to advance our strategic priorities."

Industry Context

Seres Therapeutics operates in the live biotherapeutics space, a novel approach to treating diseases by modulating the microbiome. The company's lead candidate, SER-155, targets bloodstream infections in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients, an area with high unmet medical need. Current standards of care, such as antibacterial prophylaxis with fluoroquinolones, are often inadequate, with decreasing efficacy due to rising antimicrobial resistance (AMR). Infections are a leading cause of death post-transplant, and effective prophylaxis could significantly improve patient outcomes and reduce healthcare costs. The success of viral prophylaxis like Prevymis in similar vulnerable populations provides a precedent for the market acceptance and commercial potential of such therapies. The concentrated nature of transplant centers also suggests an efficient commercial model for a new standard of care.

Comparison to Industry Standards

• US HCPs currently face a ~40% bacterial bloodstream infection (BSI) rate and ~80% febrile neutropenia (FN) rate in allo-HSCT patients, and seek a therapeutic that can reduce these to 20% and 60% respectively. SER-155's Phase 1b data showing a 77% relative risk reduction in BSIs suggests it could significantly outperform current standards.
• The market for prophylactic therapies in medically vulnerable patients is validated by products like Prevymis, which generated $785 million in worldwide sales in 2024 (a 30% growth over 2023) by reducing CMV infection in allo-HSCT and solid organ transplant recipients. This demonstrates a substantial market for effective prophylactic treatments that lower mortality and reduce the high costs associated with transplant complications (e.g., ~$180K incremental cost per patient for infections on top of ~$400K year 1 allo-HSCT costs).
• EU Key Opinion Leaders (KOLs) view BSIs as a serious problem in HCT, particularly in southern EU countries with high rates of multi-drug resistant organism (MDRO) colonization, and expressed strong support for SER-155's Phase 1b results and eagerness to participate in the Phase 2 trial, indicating global unmet need and potential market acceptance.

Related Party Transactions

• Accounts receivable due from SPN (related party) of $0.426 million as of September 30, 2025.
• Accrued liabilities due to SPN (related party) of $4.450 million as of September 30, 2025.
• Reimbursement of $2.028 million for Q3 2025 and $11.827 million for the nine months ended September 30, 2025, received from SPN (related party) for transition services provided by the company.

Stakeholder Impact

• Shareholders: Potential for significant value creation if SER-155 Phase 2 is successful, but also risk of dilution from future capital raises and uncertainty regarding funding for key clinical trials.
• Employees: Impacted by workforce reduction as part of cost-cutting measures.
• Patients (allo-HSCT): Potential to benefit from a novel therapeutic (SER-155) that could significantly reduce life-threatening bloodstream infections and improve outcomes.
• Patients (irEC): Potential to benefit from SER-155 if the investigator-sponsored trial yields positive results.
• Nestle Health Science: Continues to make payments related to the VOWST asset sale, indicating ongoing partnership and financial obligations.
• Creditors: The company retired Oaktree debt in September 2024, improving its debt profile.

Next Steps

• Finalize the SER-155 Phase 2 study protocol for bloodstream infection prevention in allo-HSCT patients.
• Secure funding and other resources to support the SER-155 Phase 2 study.
• Rapidly operationalize the SER-155 Phase 2 study once financing is in place.
• Obtain interim efficacy and safety results from the SER-155 Phase 2 study within 12 months of study initiation.
• Engage with the FDA on the design of a Phase 3 study for SER-155 based on Phase 2 interim results.
• Complete enrollment for the investigator-sponsored trial (IST) evaluating SER-155 in immune checkpoint related enterocolitis (irEC) by the end of 2025.
• Obtain initial efficacy results from the irEC IST in early 2026.
• Continue to explore potential R&D partnerships to advance development of investigational live biotherapeutics in inflammatory and immune diseases (e.g., ulcerative colitis, Crohn's disease).
• Evaluate further opportunities to extend the cash runway.

Key Dates

Recommendation

Seres Therapeutics presents a mixed but potentially promising picture. The clinical data for SER-155, particularly the 77% relative risk reduction in bacterial bloodstream infections from the Phase 1b study and the FDA's Breakthrough Therapy designation, highlight a significant therapeutic opportunity in a high-unmet-need area. The company also reported net income from continuing operations in Q3 2025, largely due to the VOWST asset sale payments, and has implemented cost-reduction measures. However, the core operations still incur a loss, and critically, the advancement of the pivotal SER-155 Phase 2 study is explicitly dependent on securing additional funding. With a cash runway projected only through Q2 2026, the company faces a near-term capital requirement. A seasoned investor would likely "hold" to monitor the company's progress in securing the necessary financing for SER-155's Phase 2, as this will be a key determinant of future value creation and could involve significant dilution if achieved through equity. The strong clinical potential is undeniable, but the financial uncertainty warrants caution.

Keywords

Seres Therapeutics, MCRB, Q3 2025, financial results, SER-155, bloodstream infections, allo-HSCT, hematopoietic stem cell transplant, live biotherapeutics, FDA Breakthrough Therapy, CARB-X, VOWST, Nestle Health Science, clinical trial, Phase 2, oncology, microbiome, immune checkpoint related enterocolitis, irEC, cash runway, biotechnology, pharmaceutical